salesforce.com, inc. (CRM) failed to extend gains with the stock declining -1.04% or $-0.85 to close the day at $80.82 on lower than average trading volume of 5.23M shares, compared to its three month average trading volume of 5.77M. The San Francisco California 94105 based company has been outperforming the application software companies by 9.0991% for last three months and its recent gains have pushed the stock slightly up 18.05% YTD, versus the application software industry which is up 10.74% for the same period. The RSI of 68.76 indicates the stock is neither overvalued nor undervalued at the current levels, hold for now.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship management to various businesses and industries worldwide. It offers enterprise cloud computing applications and platform services, including Sales Cloud that enables companies to store data, monitor leads and progress, forecast opportunities, gain insights through relationship intelligence, and collaborate around sales on desktop and mobile devices. The company also provides Service Cloud that enables companies to deliver personalized customer service and support, as well as connects their service agents with customers on various devices; and Marketing Cloud, which enables companies to plan, personalize, and optimize customer interactions. In addition, it offers Community Cloud that enables companies to engage with groups of people by giving them access to information, applications, and experts; Analytics Cloud, an application, which enables companies to deploy sales, service, marketing, and custom analytics applications using various data source; Internet of Things Cloud that enables customers to process data, as well as build personalized actions and engage with customers in real time; and App Cloud, an application development platform for companies to deliver connected applications for various business needs. Further, the company provides professional services, including consulting, deployment, training, and design and integration services to facilitate the adoption of its cloud solutions, as well as offers various education service offerings ranging from introductory online courses to advanced architecture certifications. It sells and markets services primarily through its direct sales force, as well as through consulting firms, systems integrators, and regional partners. The company has a strategic alliance with Cisco to develop IoT and contact center platforms. salesforce.com, inc. was founded in 1999 and is headquartered in San Francisco, California.
Alexion Pharmaceuticals, Inc. (ALXN) had a active trading with around 5.19M shares changing hands compared to its three month average trading volume of 2.72M. The stock traded between $130.18 and $138.21 before closing at the price of $130.39 with -1.22% change on the day. The New Haven Connecticut 06510 based company is currently trading 19.49% above its 52 week low of $109.12 and -19.51% below its 52 week high of $162. Both the RSI indicator and target price of 53.68 and $167.93 respectively, lead us to believe that it should be put on hold over the coming weeks.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia (HPP); and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH registry; Phase III clinical trials for the treatment of myasthenia gravis, neuromyelitis optica spectrum disorder, and delayed kidney transplant graft function; and Phase II clinical trials for antibody mediated rejection in presensitized renal transplant patients. It develops cPMP (ALXN 1101) that is in Phase II/III trial for treating metabolic disorders; and ALXN 1007, a novel humanized antibody in Phase II clinical trial for the treatment of anti-phospholipid syndrome and graft versus host disease. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has agreements with X-Chem Pharmaceuticals (X-Chem) to identify novel drug candidates from X-Chem’s proprietary drug discovery engine; Moderna Therapeutics, Inc. (Moderna) that provides the option to purchase drug products for clinical development commercialization of Moderna’s messenger RNA therapeutics to treat rare diseases; and Ensemble Therapeutics Corporation for the identification, development, and commercialization of therapeutic candidates based on specific drug targets. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
Colgate-Palmolive Company (CL) traded within a range of $68.03 to $69.04 after opening the day at $68.61. The company has seen its stock increase in value by 6.05% so far this year. The stock was up close to 0.57% on active volume in last trading session and closed at $69 per share. After the recent gain, the stock is currently holding -7.43% below its 52 week high of $75.38 and 8.78% above its 12-month low of $63.43. The shares are up by over 4.22% in the last three months, and the RSI indicator value of 66.7 is neither bullish nor bearish, tempting investors to stay on the sidelines.
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The company offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; personal care products comprising bar and liquid hand soaps, shower gels, shampoos, conditioners, and deodorants and antiperspirants; and home care products, such as laundry and dishwashing detergents, fabric conditioners, household cleaners, bleaches, and other similar items. It also provides pet nutrition products for everyday nutritional needs, a range of therapeutic products to manage disease conditions, and various products with natural ingredients. The company’s principal global and regional trademarks include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Softsoap, Irish Spring, Protex, Sorriso, Kolynos, elmex, Tom’s of Maine, Sanex, Ajax, Axion, Fabuloso, Soupline, and Suavitel, as well as Hill’s Science Diet, Hill’s Prescription Diet, and Hill’s Ideal Balance. It markets and sells its pet nutrition products for dogs and cats through pet supply retailers and veterinarians. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.